BRESSI E.

Last name: BRESSI E.

2023 (v1)

Publication

Metadata-only

Pathogenic pathways and therapeutic targets of inflammation in heart diseases: A focus on Interleukin-1

DelBuono M. G. Bonaventura A. Vecchie A.

Background: An exuberant and dysregulated inflammatory response contributes to the development and progression of cardiovascular diseases (CVDs). Methods: This narrative review includes original articles and reviews published over the past 20 years and found through PubMed. The following search terms (or combination of terms) were considered:...

Uploaded on: February 14, 2024
2021 (v1)

Publication

Metadata-only

Orthostatic intolerance syndromes after hematopoietic cell transplantation: clinical characteristics and therapeutic interventions in a single-center experience

Vecchie A. Thomas G. Bressi E.

Background: Hematopoietic cell transplantation (HCT) is an established and potentially curative therapeutic option for hematologic cancers. HCT survivors are at risk of developing long-term complications impacting on morbidity and mortality. Orthostatic hypotension (OH) and postural tachycardia syndrome (POTS) have been anecdotally described...

Uploaded on: April 14, 2023
2020 (v1)

Publication

Metadata-only

Phase 1B, Randomized, Double-Blinded, Dose Escalation, Single-Center, Repeat Dose Safety and Pharmacodynamics Study of the Oral NLRP3 Inhibitor Dapansutrile in Subjects With NYHA II-III Systolic Heart Failure

Wohlford G. F. Van Tassell B. W. Billingsley H. E.

ABSTRACT: The NLRP3 inflammasome has been implicated in the development and progression of heart failure. The aim of this study was to determine the safety of an oral inhibitor of the NLRP3 inflammasome, dapansutrile (OLT1177), in patients with heart failure and reduced ejection fraction (HFrEF). This was a phase 1B, randomized, double-blind,...

Uploaded on: April 14, 2023

BRESSI E.

Recent uploads